戴蓓英

戴蓓英,特聘副研究员,硕士研究生导师。本硕均就读于德国慕尼黑工业大学。在德国洪堡大学附属夏里特医学院和明斯特大学医学院攻读博士学位期间,致力于癌症的分子发病机制和耐药机制的研究,探究关键信号分子和信号通路表达异常在癌症发生发展过程中的作用。相关研究发表在《Blood》、《Hepatology》等SCI核心期刊,累积影响因子50.85分,参与撰写专著《Malignant Lymphoma》。研究成果在第58ASH年会上做会议发言,并获得Abstract Achievement Award和博士研究院Cluster of ExcellenceTravel-Grant for Female Researchers全奖。20187月加入中国药科大学药物科学研究院,专业方向为肿瘤药理学,研究内容包括血液瘤和肝癌的分子发病机制和药物新靶点的研究,以及靶向肿瘤相关巨噬细胞促进癌症治疗的分子机制研究

代表性论文:

1.B. Dai, M. Grau, M. Juilland, P. Klener, E. Höring, J. Molinsky, G. Schimmack, S.M. Aukema, E. Hoster, N. Vogt, A.M. Staiger, T. Erdmann, W. Xu, K. Erdmann, N. Dzyuba, H. Madle, W.E. Berdel, M. Trneny, M. Dreyling, K. Jöhrens, P. Lenz, A. Rosenwald, R. Siebert, A. Tzankov, W. Klapper, I. Anagnostopoulos, D. Krappmann, G. Ott, M. Thome, G. Lenz. (2017) B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood. (IF: 16.562) 129(3), 333-346.

2.B. Dai, A. Weilemann, and G. Lenz. (2016) Mantle cell lymphoma. Malignant Lymphomas: Biology and Molecular Pathogenesis. 61-74. Berlin: De Gruyter. Print.

3.W. Hu, S. Zheng, H. Guo, B. Dai, J. Ni, Y. Shi, H. Bian, L. Li, Y. Shen, M. Wu, Z. Tian, G.Liu, M. Hossain, H. Yang, D. Wang, Q. Zhang, J. Yu, L. Birnbaumer, J. Feng, D. Yu, Y. Yang. PLAGL2-EGFR-HIF-1/2α signaling loop promotes HCC progression and Erlotinib insensitivity Hepatology. (IF: 14.971) Online ahead of print.

4.N. Vogt, B. Dai, T. Erdmann, W.E. Berdel, G. Lenz. (2017) The molecular pathogenesis of mantle cell lymphoma. Leukemia & Lymphoma. (IF: 2.755) 58(7), 1530-1537.

5.T. Erdmann, P. Klener, J.T. Lynch, M. Grau, P. Vočková, J. Molinsky, D. Tuskova, K. Hudson, U.M. Polanska, M. Grondine, M. Mayo, B. Dai, M. Pfeifer, K. Erdmann, D. Schwammbach, M. Zapukhlyak, A.M. Staiger, G. Ott, W.E. Berdel, B.R. Davies, F. Cruzalegui, M. Trneny, P. Lenz, S.T. Barry, G. Lenz. (2017) Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. (IF: 16.562) 130(3), 310-322.

  

联系方式:

E-mail1620184503@cpu.edu.cn